MentisCura Diagnostics (www.mentiscura.com) today announced the launch of its first clinical center for the early detection of Alzheimer's disease and other dementias. The operational launch brings sophisticated biomarkers capable of assisting early, differential diagnosis into a clinical setting and provides for the first time cutting edge electrophysiological analysis developed by MentisCura to the general public through community physicians.
“MentisCura provides a welcome and reliable tool for diagnosing the causes of cognitive impairment and dementia. It plays a key role in our diagnostic protocol for dementia and is an important part of our follow up on disease progression and treatment efficacy”
Both the high prevalence and rapidly increasing incidence of CNS disorders are raising alarm on account of the growing burden of care associated with these diseases. According to data published by the Alzheimer's Association, Alzheimer's disease is the sixth-leading cause of death in the United States, with as many as one in eight older Americans having Alzheimer's disease in 2012. A recent World Alzheimer's Report estimated the 2010 worldwide cost of dementia to be more than $600bn.
"Our new service fulfills an important role addressing the key issues of earlier and more accurate diagnosis. Current diagnostic tools such as fMRI and PET are in a price range that precludes their use as screening tools for dementias. The low cost, high-throughput and non-invasive nature of our test makes it uniquely useful in a real world clinical setting, where physicians need to assess patients and make diagnostic decisions before these diseases have reached a late and untreatable stage. From a five-minute EEG recording using the international standard 10-20 testing protocol, our powerful analytical systems are able to provide same-day results back to physicians," said Kristinn Gretarsson, CEO of MentisCura.
"MentisCura provides a welcome and reliable tool for diagnosing the causes of cognitive impairment and dementia. It plays a key role in our diagnostic protocol for dementia and is an important part of our follow up on disease progression and treatment efficacy," commented Jon Snaedal, MD, Chief Physician of the Memory Clinic at the National Hospital of Iceland.
MentisCura's clinic offers a complete, integrated service to hospitals and general practitioners through sampling, processing and analysis of patient EEG data. The MentisCura Analysis System is a CE marked diagnostic aid, based on advanced, proprietary EEG-biomarker technology platform that accurately maps changes in electrophysiology to specific disease pathologies, through correlation with the world´s most comprehensive proprietary EEG database for dementia and cognitive disorders. The platform supports diagnoses for most common types of dementia, including Alzheimer's disease and Lewy Body Dementia.
Study points to herpes simplex virus as a risk factor for dementia